P548: BEMCENTINIB COMBINED WITH LOW-DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408)

Autor:	S. Loges, M. Heuser, J. Chromik, G. Sutamtewagul, S. Kapp-Schwoerer, M. Crugnola, N. Di Renzo, R. Lemoli, D. Mattei, I. Ben-Batalla, J. Waizenegger, L.-M. Rieckmann, M. Janning, C. D. Imbusch, N. Beumer, D. Micklem, C. Gorcea-Carson, G. Lawson, J. Nautiyal, S. Deharo, W. Fiedler, Y. Alvarado-Valero, B. Gjertsen
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	Diseases of the blood and blood-forming organs RC633-647.5
Zdroj:	HemaSphere, Vol 6, Pp 447-448 (2022)
Druh dokumentu:	article
ISSN:	2572-9241
DOI:	10.1097/01.HS9.0000845080.27665.da
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/3441cbe6330b4ee4853cf278fc6307e5 Zobrazit plný text záznamu Plný text View record in DOAJ